Researcher attestation
Aero Peptides supplies research-grade peptides for in-vitro and laboratory use only. Not for human or veterinary consumption.
By entering you confirm that:
Acceptance stored locally for 180 days.
Free US shipping over $150Free domestic shipping on all orders over $150
Metabolics & Appetite
Tirzepatide is a 39-amino-acid synthetic peptide engineered as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. A C20 fatty diacid moiety promotes albumin binding and supports a once-weekly pharmacokinetic profile in published clinical research. The peptide's discovery pharmacology, receptor signalling bias, and behaviour in large phase 3 trial cohorts spanning glycaemic control, body-weight, hepatic-fat, and renal-outcome endpoints have been characterised in peer-reviewed literature. For laboratory and research use only.
Research focus
Summary of contexts in which this compound appears in the preclinical literature. See cited studies for primary sources.
Tirzepatide is a 39-amino-acid synthetic peptide engineered as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. A C20 fatty diacid moiety promotes albumin binding and supports a once-weekly pharmacokinetic profile in published clinical research. The peptide's discovery pharmacology, receptor signalling bias, and behaviour in large phase 3 trial cohorts spanning glycaemic control, body-weight, hepatic-fat, and renal-outcome endpoints have been characterised in peer-reviewed literature. For laboratory and research use only.
Areas of research interest
Technical specifications
Compound Information
Dual GIP/GLP-1 receptor agonist (39 amino acids)
Storage & Stability
Lyophilized (powder)
-20°C • long-term stable in sealed lyophilized form
Reconstituted
2-8°C • use within 30 days of reconstitution
Light
Protect from light during storage and reconstitution
Room temperature
Short-term tolerant during shipping; minimise extended exposure above 25°C
Dosing in the literature
Observational summary of values reported in published research. Not a guide for human or animal use.
Reconstitution
Typically 1–2 mL bacteriostatic water per 10 mg vial, yielding ~5–10 mg/mL working concentration in research preparations.
Published protocols
SURPASS phase 3 trials evaluated weekly SC doses of 5, 10, and 15 mg in type 2 diabetes research cohorts. SURMOUNT trials used the same dose ladder in obesity research populations.
Half-life
~5 days in human pharmacokinetic studies, supporting once-weekly dosing.
Post-reconstitution stability
~28 days at 2–8 °C in BAC-water solution.
Values from cited SURPASS and SURMOUNT phase 3 trial publications. Clinical-trial dose ranges only — no general-use protocols established.
Sources & references
Molecular Metabolism
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
Coskun T, Sloop KW, Loghin C, et al.
2018 · DOI: 10.1016/j.molmet.2018.09.009 · PMID: 30473097
Read on PubMed ↗The Lancet
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1)
Rosenstock J, Wysham C, Frías JP, et al.
2021 · DOI: 10.1016/S0140-6736(21)01324-6 · PMID: 34186022
Read on PubMed ↗New England Journal of Medicine
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías JP, Davies MJ, Rosenstock J, et al.
2021 · DOI: 10.1056/NEJMoa2107519 · PMID: 34170647
Read on PubMed ↗The Lancet
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4)
Del Prato S, Kahn SE, Pavo I, et al.
2021 · DOI: 10.1016/S0140-6736(21)02188-7 · PMID: 34672967
Read on PubMed ↗The Lancet Diabetes & Endocrinology
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI)
Gastaldelli A, Cusi K, Fernández Landó L, et al.
2022 · DOI: 10.1016/S2213-8587(22)00070-5 · PMID: 35468325
Read on PubMed ↗The Lancet Diabetes & Endocrinology
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial
Heerspink HJL, Sattar N, Pavo I, et al.
2022 · DOI: 10.1016/S2213-8587(22)00243-1 · PMID: 36152639
Read on PubMed ↗The Lancet Diabetes & Endocrinology
Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono)
Inagaki N, Takeuchi M, Oura T, et al.
2022 · DOI: 10.1016/S2213-8587(22)00188-7 · PMID: 35914543
Read on PubMed ↗New England Journal of Medicine
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, Aronne LJ, Ahmad NN, et al.
2022 · DOI: 10.1056/NEJMoa2206038 · PMID: 35658024
Read on PubMed ↗The Lancet
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
Garvey WT, Frias JP, Jastreboff AM, et al.
2023 · DOI: 10.1016/S0140-6736(23)01200-X · PMID: 37385275
Read on PubMed ↗New England Journal of Medicine
Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis
Loomba R, Hartman ML, Lawitz EJ, et al.
2024 · DOI: 10.1056/NEJMoa2401943 · PMID: 38856224
Read on PubMed ↗10 peer-reviewed references listed. Citations verified against NCBI PubMed records. For research and educational reference only — does not constitute medical advice.
Researcher FAQ
No. Aero Peptides materials are sold exclusively for in-vitro research and laboratory analytical use. They are not intended to diagnose, treat, cure, or prevent any disease, and are not approved for human or animal administration.
By placing an order, you confirm that you are a qualified researcher and that the material will be used in accordance with all applicable institutional and jurisdictional regulations.
Each lot is independently tested for identity, purity, and mass using HPLC and mass spectrometry. The COA lists the lot number, test date, assay results, and the laboratory that performed the analysis.
Public COA documents are being prepared. In the meantime, you can request a COA for your specific lot and we’ll email it within 1 business day.
Orders ship quickly after your order is placed, from the US. Lyophilized peptides are shipped with insulation appropriate to season; short-term ambient excursions during transit do not measurably affect potency.
On receipt, store at −20°C in the sealed vial until reconstitution. See the handling matrix for full storage parameters. Tracked shipping is included; we ship to all US states and most international destinations.
Most peptides are reconstituted with bacteriostatic water (BAC). The volume depends on the target working concentration. Use our Peptide Calculator to compute volume, U-100 insulin syringe units, and doses per vial from peptide mass and target dose.
Once reconstituted, store at 2–8°C and use within 30 days. Protect the vial from light during storage and handling.
Because peptides are temperature-sensitive research materials, we cannot accept returns of opened or unsealed vials. If a shipment arrives damaged or the seal is broken on arrival, contact us within 7 days and we’ll replace or refund.
See our full returns policy for details.
Don’t see your question? Contact our research team — we typically reply within one business day.
In the same category
Frequently paired
⚠ Important research notice
Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
All clinical trial data and research findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.
